Stemline Therapeutics Inc (NASDAQ:STML) insider David Gionco sold 1,413 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $16.56, for a total value of $23,399.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
David Gionco also recently made the following trade(s):
- On Tuesday, February 27th, David Gionco sold 8,984 shares of Stemline Therapeutics stock. The stock was sold at an average price of $17.43, for a total value of $156,591.12.
- On Wednesday, January 17th, David Gionco sold 4,250 shares of Stemline Therapeutics stock. The stock was sold at an average price of $13.43, for a total value of $57,077.50.
Shares of Stemline Therapeutics Inc (STML) opened at $17.40 on Tuesday. The company has a market capitalization of $504.11, a price-to-earnings ratio of -6.77 and a beta of -0.07. Stemline Therapeutics Inc has a 12-month low of $7.30 and a 12-month high of $18.75.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in STML. Voya Investment Management LLC acquired a new stake in Stemline Therapeutics during the second quarter valued at $102,000. Royce & Associates LP acquired a new stake in Stemline Therapeutics during the fourth quarter valued at $106,000. Nationwide Fund Advisors boosted its position in Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Stemline Therapeutics during the fourth quarter valued at $170,000. Finally, Alliancebernstein L.P. acquired a new stake in Stemline Therapeutics during the second quarter valued at $178,000. 52.09% of the stock is owned by hedge funds and other institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.